Table 4.
Associations between sleep duration trajectory groups (defined over 13 years) and objective physical function at follow-up visit 13
| 40-ft walk, m/s | 4-m walk, m/s | Repeated chair stand, s | Grip strength, kg | Balance problem | |
|---|---|---|---|---|---|
| Sleep duration trajectory group | Beta (95% CI) | Beta (95% CI) | Beta (95% CI) | Beta (95% CI) | OR (95% CI) |
| Model 1 | |||||
| Persistent sufficient | REF | REF | REF | REF | REF |
| Persistent insufficient | −0.02 (−0.04, 0.01) | −0.01 (−0.03, 0.00) | 0.11 (−0.19, 0.41) | −0.52 (−1.06, 0.02) | 0.64 (0.43, 0.95)* |
| Model 2 | |||||
| Persistent sufficient | REF | REF | REF | REF | REF |
| Persistent insufficient | −0.01 (−0.04, 0.02) | −0.01 (−0.03, 0.01) | 0.06 (−0.24, 0.37) | −0.41 (−0.95, 0.13) | 0.61 (0.41, 0.92)* |
N = 1,237 for 40-ft walk. * p ≤ .05, ** p < .01, *** p < .001. Beta coefficients represent absolute differences (with 95% confidence interval) relative to the referent group. CI: confidence interval; OR: odds ratio; REF: referent group. Model 1 adjusted for race/ethnicity, difficulty paying for basics, marital status, smoking status, education, age, BMI, physical activity, clinical site, and outcome-specific variables. Model 2 adjusted for Model 1 covariates as well as self-rated health status, bodily pain, depressive symptoms, osteoarthritis, osteoporosis, angina/myocardial infarction, stroke, diabetes, cancer, hormone therapy use, menopausal status, and insomnia medication use.